Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 5, 2004 - Issue 8
Submit an article Journal homepage
268
Views
20
CrossRef citations to date
0
Altmetric
Drug Evaluation

Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease

Alicia R ZuWallack Kent County Memorial Hospital, Warwick, RI 02886, USA
&
Richard L ZuWallack St. Francis Hospital and Medical Center, Hartford, CT 06105, USA. [email protected]
Pages 1827-1835 | Published online: 25 Feb 2005

Bibliography

  • AMERICAN THORACIC SOCIETY: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD). Am. J. Respir. Crit. Care Med. (1995) 152(Suppl.):77.
  • ERS CONSENSUS STATEMENT: Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur. Respir. J. (1995) 8:1398.
  • ANON: COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. Chest (1994) 105:1411–1419.
  • GROSS NJ, SKORODIN MS: Anticholinergic, antimuscarinic bronchodilators. Am. Rev. Respir. Dis. (1984) 129:856–870.
  • HVIZDOS KM, GOA KL: Tiotropium bromide. Drugs (2002) 62:1195–1203.
  • HANSEL TT, BARNES PJ: Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs Today (2002) 38:585–600.
  • BARNES PJ: The pharmacological properties of tiotropium. Chest (2000) 117:63s–66s.
  • DISSE B, REICHL R, SPECKG, TRAUNECKER W, ROMINGER KL, HAMMER R: Ba679BR, a new long-acting antimuscarinic bronchodilator: predicted clinical aspects. Lift Sci. (1993) 52:537–555.
  • DISSE B, SPECK GA, ROMINGER KL, WITEK TJ, HAMMER R: Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Lift Sci. (1999) 64:457–464.
  • DISSE B, ROMINGER K, SERBY CW, SOUHRADA JF, WITEK TJ: The pharmacokinetic (PK) profile of tiotropium during long-term treatment in stable COPD. Am. J. Respir. Crit. Care Med. (1997) 155:A524.
  • VAN NOORD JA, SMEETS JJ, CUSTERS FLJ, KORDUCKI L, CORNELISSEN PJG: Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur. Respir. J. (2002) 19:639–644.
  • MAESEN FP, SMEETS JJ, MA, WALD FD, CORNELISSEN PJ: Ba 679 Br, a new long-acting antimuscarinic bronchodilator: a pilot dose-escalation study in COPD. Eur. Respir. J. (1993) 6:1031–1036.
  • LITTNER MR ILOWITE JS DP et al.: Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2000) 161:1136–1142.
  • CHODOSH S, FLANDERS JS, S, SERBY CW, D, WITEK TJ: Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J. Aerosol. Med. (2001) 14:309–315.
  • CASABURI R, BRIGGS DD, DONOHUE JF, SERBY CW, MENJOGE SS, WITEK TJ: The spirometric efficacy of once-daily dosing with tiotropium in stable COPD. A 13-week multicenter study. Chest (2000) 118:1294–1302.
  • CASABURI R, MAHLER DA, PW et al.: A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. (2002) 19:217–224.
  • TASHKIN D, KESTEN S: Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. (2003) 123:1441–1449.
  • CELLI B, ZUWALLACK R, WANG S, KESTEN S: Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. (2003) 124:1743–1748.
  • O'DONNELL DE, FLUGE T, F et al.: Effects of tiotropium on lung hyperinflation, dyspnoea, and exercise tolerance in COPD. Eur. Respir. J. (2004) 23:832–840.
  • MAHLER DA, WEINBERG DH, WELLS CK, FEINSTEIN AR: The measurement of dyspnea: contents, interobserver agreement, and physiologic correlations of two new clinical indexes. Chest (1984) 85:751–758.
  • VAN NOORD JA, BANTJE TA, ELAND ME, KORDUCKI L, CORNELISSEN PJ: A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax (2000) 55:289–294.
  • VINCKEN W, VAN NOORD JA GREEFHORST AP et al.: Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. (2002) 19:209–216.
  • BRUSASCO V, HODDER R, MIRAVITLLES M, KORDUCKI L, TOWSE L, KESTEN S: Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax (2003) 58:399–404.
  • VAN NOORD JA, AUMANN J, JANSSENS E et al.: Tiotropium maintenance therapy in patients with COPD and the 24-h spirometric benefit of adding once or twice daily formoterol during 2-week treatment periods. Respir. Crit. Care Med. (2003):A95.
  • VAN NOORD JA, AUMANN J, JANSSENS E, MUELLER A, CORNELISSEN PJ: Comparison of once daily tiotropium, twice daily formoterol and the free combination, once daily, in patients with COPD. Am. J. Respir. Crit. Care Med. (2003):A320.
  • ANON: The Combivent Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest (1997) 112:1514–1521.
  • NOORD JA, MUNCK DR, BANTJE TA, HOP WC, AKVELD ML, BOMMER AM: Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur. Respir. (2000) 15:878–885.
  • CALVERLEY P, PAUWELS R, VESTBO J et al.: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2003) 361:449–456.
  • MAHLER DA, WIRE P, HORSTMAN D et al.: Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2002) 166:1084–1091.
  • HANANIA NA, DARKEN P, HORSTMAN D et al.: The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest (2003) 124:834–843.
  • MASSEY KL, GOTZ VP: Ipratropium bromide. Drug Intell. Clin. Pharm. (1985) 19:5–12.
  • BARNES PJ: New developments in anticholinergic drugs. Eur. Respir. Rev. (1996) 39:290–294.

Websites

  • http://www.goldcopd.com Initiative for Chronic Obstructive Pulmonary Disease Workshop Report: Updated 2003. Accessed July (2003).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.